{"id":"NCT04040192","sponsor":"Pfizer","briefTitle":"A Study to Evaluate Long-Term Maintenance Treatment With Once Daily Crisaborole Ointment 2% in Pediatric and Adult Participants With Mild-to-Moderate Atopic Dermatitis","officialTitle":"A Phase 3, Randomized, Double-Blind, Vehicle-Controlled Study to Evaluate the Efficacy and Safety of Maintenance Treatment and Flare Reduction With Crisaborole Ointment, 2%, Once Daily Over 52 Weeks in Pediatric and Adult Participants (Ages 3 Months and Older) With Mild-to-Moderate Atopic Dermatitis, Who Responded to Twice Daily Crisaborole Ointment, 2%, Treatment","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-09-12","primaryCompletion":"2022-01-19","completion":"2022-01-19","firstPosted":"2019-07-31","resultsPosted":"2023-03-08","lastUpdate":"2023-03-08"},"enrollment":620,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Atopic Dermatitis"],"interventions":[{"type":"DRUG","name":"Crisaborole 2%","otherNames":[]},{"type":"DRUG","name":"Vehicle","otherNames":[]}],"arms":[{"label":"Crisaborole 2%","type":"EXPERIMENTAL"},{"label":"Vehicle","type":"PLACEBO_COMPARATOR"}],"summary":"This study will evaluate crisaborole therapy once daily (QD) as a long-term topical maintenance therapy for the reduction of flare in responders to crisaborole twice daily (BID) treatment.","primaryOutcome":{"measure":"Duration of Flare-Free Maintenance Until Onset of First-Flare During the Double Blind (DB) Period","timeFrame":"From randomization to first flare or last ISGA assessment (up to 52 weeks)","effectByArm":[{"arm":"Vehicle QD","deltaMin":30,"sd":28},{"arm":"Crisaborole 2% QD","deltaMin":111,"sd":56}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0034"}]},"eligibility":{"minAge":"3 Months","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":null},"locations":{"siteCount":44,"countries":["United States","Australia","Canada","China","Israel","Turkey (TÃ¼rkiye)"]},"refs":{"pmids":["38546803","37184828"],"seeAlso":["https://pmiform.com/clinical-trial-info-request?StudyID=C3291035"]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":497},"commonTop":["Application site pain","Dermatitis atopic","Upper respiratory tract infection","Application site infection","Nasopharyngitis"]}}